- Home
- / Arcutis Biotherapeutics
- / Financials
Header placeholder lorem ipsum dolor sit amet, consectetur adipiscing elit.
Arcutis Biotherapeutics financials data including stock price, CreditSafe score, income statement, balance sheet, and cash flow.
Stock Price
$8.6
2024-10-29
Market Capitalization
$1 B
2024-10-29
Revenue
$376.1 M
FY, 2025
CreditSafe Score
?
Score changed on Jun 08, 2026
Premium Content only available in Craft’s Intelligence Portal
View 30+ financial ratio metrics including price-to-earnings ratio, debt-to-assets ratio, gross profit margin, and more.
Financial ratio metrics help evaluate the financial strength of a company, and help raise red flags that can indicate potential risk, fulfillment challenges, or even possible bankruptcy.
Learn moreFinancial Statements
| USD | FY, 2017 | FY, 2018 | FY, 2020 | FY, 2021 | FY, 2022 | FY, 2023 | FY, 2024 | FY, 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 3.7M | 59.6M | 196.5M | 376.1M | ||||
| Cost of goods sold | 5.0M | 19.1M | 36.7M | |||||
| Gross profit | 54.6M | 177.4M | 339.4M | |||||
| Gross profit margin, % | 91.6% | 90.3% | 90.2% | |||||
| General and administrative expense | 695.0K | 1.8M | 21.3M | 61.0M | 122.1M | 185.1M | 229.4M | 274.6M |
| Operating expense total | 4.1M | 19.7M | 136.6M | 304.6M | 295.7M | 305.8M | 351.6M | |
| EBIT | (4.1M) | (19.7M) | (136.6M) | (206.5M) | (301.6M) | (241.1M) | (128.4M) | (12.2M) |
| EBIT margin, % | -8183.0% | -404.5% | -65.3% | -3.3% | ||||
| Interest income | 8.9M | |||||||
| Interest expense | 29.7M | 22.2M | ||||||
| Pre tax profit | (255.7M) | (130.4M) | (8.2M) | |||||
| Income tax expense | 3.1M | 647.0K | 1.2M | |||||
| Net Income | (5.0M) | (19.3M) | (135.7M) | (206.4M) | (311.5M) | (262.1M) | (140.0M) | (16.1M) |
| EPS | (5.7) | (3.8) | (1.2) | (0.1) |